Body Check

1 dose annually

2 doses with minimum interval of 4 weeks for child below aged 9 who has never received any seasonal influenza vaccine

• Protection begin 2 weeks after vaccination

Children younger than 5, but especially children younger than 2 years, elderly and those with weaken immunity.

Fever, injection site reaction (pain/erythema/swelling), irritability and headache

• Severe allergic reaction to any component of this vaccine

1 dose annually

2 doses with minimum interval of 4 weeks for child below aged 9 who has never received any seasonal influenza vaccine

• Protection begin 2 weeks after vaccination

Children younger than 5 years old

Fever, runny nose, nasal congestion, sore throat

• Severe allergic reaction to any component of Flumist
• Children aged 2 to 4 with asthma or history of wheezing in past 12 months
• Asthma sufferer and pregnant lady
• Concomitant aspirin therapy

Once per year

• For people over 65 years old, this vaccine is potentially more effective than standard quadrivalent flu vaccines
• Does not contain egg component

Over 65 years old. Between 18-64 years old with chronic illness eg. respiratory illness, diabetes, heart disease, chronic renal disease, liver disease or immunocompromised

Fever, injection site reaction (pain/erythema/swelling)

• Severe allergic reaction to any component of this vaccine
• Below 9 years old

4 doses at 2, 4, 6 months and 15-18 months

• Combine DTaP-IPV & Hib vaccine, can reduce the total number of injections from 8 to 4

Infant

Fever, injection site reaction (pain/erythema/swelling), injection nodule, unusual crying, irritability, loss of appetite, vomiting, diarrhea and somnolence

• Severe allergic reaction to any component of this vaccine
• Encephalopathy of unknown cause, occurring within 7 days following previous vaccination with a pertussis containing vaccine

4 doses at aged 2, 4, 6 months and 15-18 months

• 30-40% more Pertussis prevention than traditional DTaP-IPV vaccine
• Combine 5in1 & Hepatitis B vaccine, can reduce the total number of injections from 10 to 4

Infant

Fever, injection site reaction (pain/erythema/swelling), injection nodule, unusual crying, irritability, loss of appetite, vomiting, diarrhea and somnolence

• Severe allergic reaction to any component of this vaccine
• Encephalopathy of unknown cause, occurring within 7 days following previous vaccination with a pertussis containing vaccine

For preterm infants (<37 weeks gestation at birth) : 4 doses at aged 2, 4, 6 months and 11-15 months

For normal babies: 3 doses at aged 2, 4 months and 11-15 months

For aged over 7 to under 12 months: 3 doses (dose 1 & 2 with minimum interval of 4 weeks; dose 3 after 12 months old, separated from dose 2 by minimum of 8 weeks)

For aged over 12 to under 24 months: 2 doses with minimum interval of 8 weeks

For aged over 2: 1 dose

• PCV15 includes all PCV13 serotypes plus 22F and 33F
• PCV13 and PCV15 can be used interchangeably

Infant, immunodeficient individual, functional or anatomic asplenia, cochlear implants

Fever, injection site reaction (pain/erythema/swelling), irritability, loss of appetite, vomiting, diarrhea, upper respiratory tract infection, rash, eczema and itching

• Severe allergic reaction to any component of this vaccine or any diphtheria toxoid-containing vaccine

For aged 6 weeks to 6 months: 4 doses at aged 2, 4, 6 months and 12-15 months

For aged over 7 to under 12 months: 3 doses (dose 1 & 2 with minimum interval of 4 weeks; dose 2 & 3 with minimum interval of 8 weeks)

For aged over 12 to under 24 months: 2 doses with minimum interval of 8 weeks

For aged over 2: 1 dose

• PCV20 includes all PCV13 serotypes plus 7 extra

Infant, immunodeficient individual, functional or anatomic asplenia, cochlear implants

Fever, injection site reaction (pain/erythema/swelling)

• Severe allergic reaction to any component of this vaccine or any diphtheria toxoid-containing vaccine

2 doses with at least 1 month interval

• Early protection from 15 months old onwards

Young child, Pregnant women

Fever, injection site reaction (pain/erythema/swelling), irritability, vomiting, diarrhea, upper respiratory tract infection, rash and eczema

• Pregnancy
• Severe allergic reaction to any component of this vaccine
• Immunodeficiency

2 doses with 6 -12 months apart

• Protecton against Hepatitis A virus starts 28 days after 1st vaccination

Child care centre attendee and children who have started eating high-risk food such as fish and shellfish, Travellers to endemic areas of hepatitis A, Persons with chronic liver diseases.

Fever, injection site reaction (pain/erythema/swelling), irritability, loss of appetite, vomiting, diarrhea, headache, somnolence and arthralgia

• Severe allergic reaction to any component of this vaccine

3 doses: 1-month interval between first and second doses, and third dose 5 months after second dose

• Full response occurs in about 90–95% of individuals

Babies born to carrier mothers. People who share needles, syringes, or other drug-injection equipment. Travellers to regions with increased rates of hepatitis B. People with chronic liver disease, kidney disease, HIV infection, or diabetes

Fever, injection site reaction (pain/erythema/swelling), irritability and headache

• Severe allergic reaction to any component of this vaccine

For aged 1.5-6 months: 4 doses with minimum 4-week interval for the first three doses, fourth dose at least 8 weeks after third dose and at 12 months old or above

For aged 7-11 months: 3 doses with minimum 4-week interval for the first two doses, third dose at least 8 weeks after second dose and at 12 months old or above

For aged 12-14 months: 2 doses with minimum 8-week interval

For aged 15-59 months: 1 dose

• To reduce the number of injections, 5-in-1 or 6-in-1 vaccine can be considered as they already included this vaccine

3 months to 3 years old

Fever, injection site reaction (pain/erythema/swelling), irritability, loss of appetite and somnolence

• Severe allergic reaction to any component of this vaccine

Age 9-14: 2 doses series on a 0-,6-month schedule

Age 15 or over: 3 doses series on a 0-,2-,6-month schedule

• Provide extra 85-90% of protection against Vaginal and Cervical cancer when compare to other HPV vaccine.

Recurrent HPV infection, Immunodeficient individual, Smoker

Mild redness and swelling at injection site. Occasionally, fever or headache might occur

• Hypersensitivity, including severe allergic reactions to yeast (a vaccine component), or after a previous dose of GARDASIL 9 or GARDASIL
• Pregnant women
• Those with fever or suffering from moderate to severe illness

9 months to 17 years old: 2 doses series, with interval of 12-24 months

18 years old and above: 1 dose only

• 99.2% of young children (9 to 18 months old) get protection 28 days after receiving one dose of Japanese encephalitis vaccine

Newborn to 14 years old , People who stay outdoor most of the time

Fever, injection site reaction (pain/erythema/swelling), unusual crying, loss of appetite, headache, vomiting and somnolence

• Infant under 9 months old
• Severe allergic reaction to any component of this vaccine

Over 12 months : 1 dose

• The only ACWY vaccine approved by both FDA & EMA in Hong Kong

Borders in dormitories, students planning for overseas studies and travellers to high-risk countries

Fever, injection site reaction (pain/erythema/swelling), irritability, loss of appetite, vomiting, diarrhea and somnolence

• Severe allergic reaction to any component of this vaccine

For aged 6 weeks to 5 months: 3 doses, minimum 2-month interval between first two doses, then 1 booster dose at 12 months old or above

For aged 6-11 months: 2 doses with minimum 2-month interval and second dose given at 12 months old or above

Over 12 months : 1 dose

• Contain extra Y and W-135 strain than the China meninococcal vaccine
• Can be given as early as 6 weeks old
• Though Hong Kong has a low meningococcal infection rate, vaccination is still recommended for high-risk group

Under 1 year old, borders in dormitories, students planning for overseas studies and travellers to high-risk countries

Fever, injection site reaction (pain/erythema/swelling), irritability, loss of appetite, vomiting, diarrhea and somnolence

• Severe allergic reaction to any component of this vaccine

2-23 months old : 3 doses, at least 2 months between each dose

2 years old and above : 2 doses, at least 1 month apart

• The only Meningococcal B vaccine indicated for paediatric patients
• Though Hong Kong has a low meningococcal infection rate, vaccination is still recommended for high-risk group

Immunodeficient individual, borders in dormitorie, students planning for overseas studies and travellers to high-risk countries

Fever, injection site reaction (pain/erythema/swelling), unusual crying, irritability, loss of appetite, vomiting, diarrhea, somnolence and rash

• Severe allergic reaction to any component of this vaccine

2 doses with 3 months interval

• Early protection from 15 months old onwards

Young child, Pregnant women

Fever, injection site reaction (pain/erythema/swelling), upper respiratory tract infection and rash

• Pregnancy
• Severe allergic reaction to any component of this vaccine
• Immunodeficiency

2 doses with 3 months interval

• Early protection from 15 months old onwards

Young child, Pregnant women

Fever, injection site reaction (pain/erythema/swelling), irritability, vomiting, diarrhea, upper respiratory tract infection, rash and eczema

• Pregnancy
• Severe allergic reaction to any component of this vaccine
• Immunodeficiency

Pre-Exposure : 2-Dose regimen at Day 0 & 7

Post-Exposure : 4-Dose regimen at Day 0,3,7 & 14

• It can be used before and after exposure to the rabies virus, as a primary vaccination or as a booster dose.

People in contact with potentially rabid animal species (such as dogs, cats, skunks, raccoons, bats). Adults living in or travelling to enzootic areas.

Mild redness and swelling at injection site

• Fever
• Severe allergic reaction (e.g. anaphylaxis) to any component of Verorab

2 doses with at least 4 weeks apart, first dose to be taken before 20 weeks old

• Early protction, infant can finished the 2 doses course as early as 10 weeks old

4 to 23 months

Fever, irritability, loss of appetite, vomiting, diarrhea

• Severe allergic reaction to any component of this vaccine
• History of intussusception or uncorrected congenital malformation of the gastrointestinal tract that would predispose the infant to intussusception
• History of severe combined immunodeficiency disease

3 doses with at least 4 weeks apart, first dose to be taken before 12 weeks old

• Pentavalent vaccine

4 to 23 months

Fever, irritability, loss of appetite, vomiting, diarrhea

• Severe allergic reaction to any component of this vaccine
• History of intussusception or uncorrected congenital malformation of the gastrointestinal tract that would predispose the infant to intussusception
• History of severe combined immunodeficiency disease

• Newborns to under 1 year old : 1 dose only
• Up to 24 months old who remain vulnerable to severe RSV disease : may consider additional dosage

• Unlike a vaccine that trains the immune system, Beyfortus provides pre-formed antibodies, offering immediate protection.

Newborns and under 1 year old

Fever, injection site reaction (pain/erythema/swelling)

• Severe allergic reaction to any component of this vaccine

The vaccine should be given at least two weeks prior to departure . Revaccination should be considered every three years for those at continuous risk of infection.

• Antibodies appear after approximately 7 to 15 days after the injection. Persistence of the antibody response is at least 3 years.

Those going to typhoid endemic areas, in particular long-stay travellers and those visiting rural areas where food and beverage choices may be limited.

Mild redness and swelling at injection site

• Fever
• Severe allergic reaction (e.g. anaphylaxis) to any component of Typhim VI

1 dose only

• Cover more serotypes than any other pneumococcal vaccine

Immunodeficient individual, Functional or anatomic asplenia, Cochlear implants

Mild redness and swelling at injection site

• Severe allergic reaction (e.g. anaphylaxis) to any component of Pneumovax 23

2 doses with 6-12 months apart

• Protection against Hepatitis A virus starts 28 days after 1st vaccination

People with chronic liver disease, IV drug users, and men who have sex with men

Fever, injection site reaction (pain / swelling)

• Severe allergic reaction to any component of this vaccine

3 doses: 1-month interval between first and second doses, and 3rd dose 5 months after second dose.

• Full response occurs in about 90-95% of individuals

Born in HK before 1988 ; People who share needles, syringes, or other drug-injection equipment. Travellers to regions with increased rates of hepatitis B. People with chronic liver disease, kidney disease, HIV infection, or diabetes

Fever, injection site reaction (pain/erythema/swelling)

• Severe allergic reaction to any component of this vaccine

A series of 3 doses on a 0-,1-,6-month schedule

• Full response occurs in about 90–100% of individuals

Those born in Hong Kong prior to 1988 People who share needles, syringes, or other drug-injection equipment. Travellers to regions with increased rates of hepatitis B. People with chronic liver disease, kidney disease, HIV infection, or diabetes

Mild redness and swelling at injection site

• Severe allergic reaction (e.g. anaphylaxis) to any component of Twinrix

2 doses: second dose 2 to 6 months after first dose

• Only shingles vaccine provide >90% protection in all segments studied

Previous shingles infection, immunodeficient individual eg Diabetics

Mild redness and swelling at injection site. Occasionally, associated with syncope

• History of anaphylactic reaction to any component of the vaccine

Only 1 injection

• Bivalent protein subunit vaccine

Below 1 years old , chronic lung or heart disease, weakened immune system

Injection site reaction (pain/erythema/swelling), headache, nausea

• Severe allergic reaction to any component of this vaccine

Only 1 injection

• Protection efficacy of 80-95% for aged 60 and above, with at least one chronic illness

60 years old and above with at least one chronic illness (COPD, Diabetes, Heart disease)

Mild redness and swelling at injection site

• History of anaphylactic reaction to any component of the vaccine

• Up to 300 common food and environmental allergens and molecular components
• Needs only a small blood sample; suitable for children aged 2 or above
• Comes with follow-up advice on allergic reactions
• CCD-Inhibition technology screens out false positives
• Cross-reactive allergens are grouped by similar IgE response — dog and cat hair, for example, belong to the same lipocalin IgE group

• Tests for 84 common allergens
• Includes Total IgE (immediate allergic response)
• Specific IgE to food allergens: vegetables, seeds and nuts, grains, legumes, fruit, dairy, egg, meat, shellfish and fish
• Specific IgE to inhalant and other allergens: atopic dermatitis, animal dander, pollen, insects, yeasts and moulds, dust mites and latex
• The price includes a doctor’s explanation of the report

• Measures the level of HPV antibodies in the blood
• Uses antibody–antigen binding to cover four of the nine-valent HPV vaccine’s antibodies: HPV6, 11, 16 and 18
• A quantitative assay measures the combined level of the four antibodies
• Where the HPV vaccine was given within the manufacturer’s stated period, the corresponding antibodies can be detected after vaccination, confirming that protection is adequate

• Developed by the research team at The Chinese University of Hong Kong (CUHK), applying next-generation DNA sequencing to early nasopharyngeal cancer screening
• A single blood draw, combining Polymerase Chain Reaction (PCR) and Next-generation Sequencing (NGS) to analyse NPC-associated DNA in blood plasma
• Sensitivity greater than 97%, with very few cases missed; the false-positive rate is very low (0.7%)
• No hospital admission — a blood draw is all that is needed, and the procedure is simple and non-invasive
• Validated in a clinical study involving 20,000 individuals